- Home
- WDI vs LBRX Comparison
WDI vs LBRX Comparison
Compare WDI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDI | LBRX |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 602.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WDI | LBRX |
|---|---|---|
| Price | $13.69 | $30.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 200.0K | ★ 300.6K |
| Earning Date | 01-01-0001 | 05-09-2026 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.91 | $13.40 |
| 52 Week High | $15.28 | $32.91 |
Technical Indicators
Market Signals| Indicator | WDI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 65.02 |
| Support Level | $13.60 | $21.90 |
| Resistance Level | $13.70 | N/A |
| Average True Range (ATR) | 0.14 | 1.92 |
| MACD | 0.02 | 0.43 |
| Stochastic Oscillator | 47.76 | 75.71 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund will seek capital appreciation. The fund seeks to achieve its investment objectives by investing, under normal market conditions, across fixed income sectors and securities in seeking to deliver a well-diversified portfolio.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.